

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor's Application of

Atty Dkt. 620-148

DAVIS et al.

C# M#

Serial No. 09/897,412

Group Art Unit: 1743

Filed: July 3, 2001

Examiner:

Date: November 23, 2001

Title: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Information Disclosure Statement, PTO-1449, references and search report; Statement with paper 0.00

and computer-readable copies of Sequence Listing; copy of Notice to Comply dated 10/22/01;

Copy of Withdrawal dated 10/22/01

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:eaw

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

DAVIS et al.

Serial No. 09/897,412

Filed: July 3, 2001

For: **USE OF SECRETIN-RECEPTOR LIGANDS IN
TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)**



Atty. Ref.: 620-148

Group: 1743

Examiner:

November 23, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Notice to Comply dated October 22, 2001 (copy attached),
entry and consideration of the following amendments and remarks are requested.

IN THE SPECIFICATION

Amend the specification as follows.

Page 13, delete the paragraph spanning lines 8-28, and insert the following
therefor:

--For example, Gespach et al (1986) describe four synthetic secretin analogues
including one corresponding to porcine secretin substituted at the N-terminus by
sequence portions of vasoactive intestinal peptide (VIP), i.e. Ala4-Val5-pSN, together
with Tyr1-Ala2-Glu3-pSN, Gln3-pSN, Phe1-Phe2-Trp3-Lys4-pSN (SEQ ID NO:13). Konig
et al (1977) describe Ala4-pSN. Gardener et al (1976) describe the secretin fragment